NASDAQ:GRCL

Gracell Biotechnologies Competitors

$12.24
-0.56 (-4.38 %)
(As of 04/20/2021 12:10 PM ET)
Add
Compare
Today's Range
$12.09
Now: $12.24
$12.47
50-Day Range
$12.90
MA: $18.57
$24.97
52-Week Range
$12.30
Now: $12.24
$33.70
Volume972 shs
Average Volume146,147 shs
Market Capitalization$802.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Gracell Biotechnologies (NASDAQ:GRCL) Vs. SEER, NUVB, IBRX, IMCR, BCAB, and CGEM

Should you be buying GRCL stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Gracell Biotechnologies, including Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), Immunocore (IMCR), BioAtla (BCAB), and Cullinan Oncology (CGEM).

Gracell Biotechnologies (NASDAQ:GRCL) and Seer (NASDAQ:SEER) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Earnings & Valuation

This table compares Gracell Biotechnologies and Seer's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gracell BiotechnologiesN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Profitability

This table compares Gracell Biotechnologies and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gracell BiotechnologiesN/AN/AN/A
SeerN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and recommmendations for Gracell Biotechnologies and Seer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gracell Biotechnologies00403.00
Seer02202.50

Gracell Biotechnologies presently has a consensus price target of $34.50, indicating a potential upside of 181.86%. Seer has a consensus price target of $68.00, indicating a potential upside of 40.99%. Given Gracell Biotechnologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Gracell Biotechnologies is more favorable than Seer.

Summary

Gracell Biotechnologies beats Seer on 3 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Gracell Biotechnologies (NASDAQ:GRCL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Nuvation Bio and Gracell Biotechnologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
Gracell Biotechnologies00403.00

Nuvation Bio presently has a consensus target price of $17.40, suggesting a potential upside of 66.83%. Gracell Biotechnologies has a consensus target price of $34.50, suggesting a potential upside of 181.86%. Given Gracell Biotechnologies' higher probable upside, analysts clearly believe Gracell Biotechnologies is more favorable than Nuvation Bio.

Profitability

This table compares Nuvation Bio and Gracell Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/A

Earnings & Valuation

This table compares Nuvation Bio and Gracell Biotechnologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/AN/AN/A

ImmunityBio (NASDAQ:IBRX) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Earnings & Valuation

This table compares ImmunityBio and Gracell Biotechnologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/AN/AN/A

Profitability

This table compares ImmunityBio and Gracell Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for ImmunityBio and Gracell Biotechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Gracell Biotechnologies00403.00

ImmunityBio currently has a consensus target price of $25.00, suggesting a potential upside of 50.06%. Gracell Biotechnologies has a consensus target price of $34.50, suggesting a potential upside of 181.86%. Given Gracell Biotechnologies' higher possible upside, analysts plainly believe Gracell Biotechnologies is more favorable than ImmunityBio.

Summary

Gracell Biotechnologies beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

Gracell Biotechnologies (NASDAQ:GRCL) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Gracell Biotechnologies and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gracell BiotechnologiesN/AN/AN/A
ImmunocoreN/AN/AN/A

Valuation & Earnings

This table compares Gracell Biotechnologies and Immunocore's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gracell BiotechnologiesN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Gracell Biotechnologies and Immunocore, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gracell Biotechnologies00403.00
Immunocore01202.67

Gracell Biotechnologies presently has a consensus target price of $34.50, indicating a potential upside of 181.86%. Immunocore has a consensus target price of $54.3333, indicating a potential upside of 43.51%. Given Gracell Biotechnologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Gracell Biotechnologies is more favorable than Immunocore.

Summary

Gracell Biotechnologies beats Immunocore on 3 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Gracell Biotechnologies (NASDAQ:GRCL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Profitability

This table compares BioAtla and Gracell Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for BioAtla and Gracell Biotechnologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Gracell Biotechnologies00403.00

BioAtla currently has a consensus target price of $58.00, indicating a potential upside of 22.18%. Gracell Biotechnologies has a consensus target price of $34.50, indicating a potential upside of 181.86%. Given Gracell Biotechnologies' higher possible upside, analysts plainly believe Gracell Biotechnologies is more favorable than BioAtla.

Valuation & Earnings

This table compares BioAtla and Gracell Biotechnologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Gracell BiotechnologiesN/AN/AN/AN/AN/A

Summary

Gracell Biotechnologies beats BioAtla on 1 of the 1 factors compared between the two stocks.

Gracell Biotechnologies (NASDAQ:GRCL) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Valuation and Earnings

This table compares Gracell Biotechnologies and Cullinan Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gracell BiotechnologiesN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Gracell Biotechnologies and Cullinan Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gracell Biotechnologies00403.00
Cullinan Oncology01302.75

Gracell Biotechnologies currently has a consensus target price of $34.50, indicating a potential upside of 181.86%. Cullinan Oncology has a consensus target price of $48.75, indicating a potential upside of 48.95%. Given Gracell Biotechnologies' stronger consensus rating and higher possible upside, research analysts clearly believe Gracell Biotechnologies is more favorable than Cullinan Oncology.

Profitability

This table compares Gracell Biotechnologies and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gracell BiotechnologiesN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Summary

Gracell Biotechnologies beats Cullinan Oncology on 3 of the 3 factors compared between the two stocks.


Gracell Biotechnologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SEER
Seer
1.2$48.23-3.6%$3.04 billionN/A0.00Increase in Short Interest
Gap Up
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$10.43-5.1%$2.18 billionN/A0.00
IBRX
ImmunityBio
1.7$16.66-1.8%$1.85 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$37.86-3.5%$1.69 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.5$47.47-1.0%$1.61 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.3$32.73-2.0%$1.40 billionN/A0.00Analyst Report
News Coverage
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$36.30-4.0%$1.32 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
1.9$28.77-1.9%$1.30 billionN/A0.00Analyst Downgrade
EWTX
Cricut
1.1$25.69-4.2%$1.27 billionN/A0.00Analyst Report
News Coverage
Gap Up
KNTE
Kinnate Biopharma
1.7$27.46-0.9%$1.20 billionN/A0.00Increase in Short Interest
Vor Biopharma logo
VOR
Vor Biopharma
1.9$26.60-7.4%$1.06 billionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$16.99-1.5%$962.29 millionN/A0.00Analyst Report
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.17-0.5%$882.77 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$31.32-5.4%$880.90 millionN/A0.00
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$25.24-3.1%$828.16 millionN/A0.00
Pharming Group logo
PHAR
Pharming Group
0.0$12.95-0.9%$827.27 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.32-5.8%$737.78 millionN/A0.00
FNCH
Finch Therapeutics Group
2.0$14.10-9.9%$730.28 millionN/A0.00Analyst Report
News Coverage
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$15.45-0.4%$630.05 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$13.39-0.4%$517.26 millionN/A0.00News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$15.83-1.5%$506.09 millionN/A0.00Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$10.80-3.9%$482.45 millionN/A0.00Gap Up
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.24-6.0%$435.28 millionN/A0.00Gap Up
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$16.45-4.0%$429.64 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$18.40-0.2%$417.84 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$12.89-2.4%$403.76 millionN/A0.00Gap Down
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$12.62-7.5%$400.10 millionN/A0.00Gap Up
PRTG
Portage Biotech
0.0$29.40-8.2%$355.24 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.84-7.2%$283.89 millionN/A-2.57Gap Up
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.09-1.3%$262.02 millionN/A-2.41
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.58-2.7%$245.04 millionN/A0.00
VINC
Vincerx Pharma
1.0$17.24-0.1%$240.80 millionN/A0.00Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$9.25-6.8%$188.90 millionN/A0.00Increase in Short Interest
News Coverage
LBPH
Longboard Pharmaceuticals
1.9$10.21-0.8%$171.37 millionN/A0.00Quiet Period Expiration
GANX
Gain Therapeutics
1.7$13.60-2.7%$158.29 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.22-3.4%$152.49 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$7.00-2.1%$131.51 millionN/A0.00News Coverage
LGVN
Longeveron
0.3$6.26-0.5%$118.10 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$32.00-7.8%$80.60 millionN/A0.00News Coverage
UPC
Universe Pharmaceuticals
0.0$3.45-2.9%$77.21 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$15.04-1.9%$58.78 millionN/A0.00Decrease in Short Interest
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.19-1.0%$52.17 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.59-0.2%$46.57 millionN/A0.00
VIRX
Viracta Therapeutics
1.7$7.65-1.3%$39.06 millionN/A0.00
VYNT
Vyant Bio
0.0$3.42-1.2%$38.08 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.12-6.7%$34.28 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.39-3.6%$29.90 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.04-5.4%$21.07 millionN/A0.00News Coverage
Gap Up
BCTX
BriaCell Therapeutics
0.0$2.87-8.7%$2.41 millionN/A0.00Gap Up
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.60-1.5%$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.